1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62C0DD98E80732CB0852584730026D267
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-patient-advocacy-2020-abiding-ethical-boundaries-regulatory-impact-united-states?opendocument
18
19opendocument
203.227.3.146
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Patient Advocacy

Patient Advocacy 2020: Abiding Ethical Boundaries & Regulatory Impact on Patient Advocacy in the United States

ID: 5579


Features:

20 Info Graphics

4 Data Graphics

25+ Metrics

5 Narratives


Pages/Slides: 32


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Patient Advocacy 2020: Abiding Ethical Boundaries & Regulatory Impact on Patient Advocacy in the United States”

STUDY OVERVIEW

As treatment options in the United States become more complex and plentiful, it is important for pharmaceutical organizations to collaborate with key patient advocacy groups to educate the public about new treatments and scientific advancements. At the same time, organizations must remain compliant with the ever-growing regulations surrounding relationships with external patient groups.

Best Practices, LLC undertook this benchmarking research to identify effective ways for biopharmaceutical organizations to collaborate with patient advocacy groups in the United States. In particular, this research provides insights around ethical boundaries and the regulatory landscape for patient advocacy partnerships in the US. This study also contains a chapter with qualitative data from benchmark partners regarding adherence to ethical boundaries and addressing regulatory impact for patient advocacy initiatives in the United States.

KEY TOPICS

  • Understanding the Advocacy landscape
  • Strategies to address regulatory impact
  • Clinical trials funding
  • Adhering to ethical boundaries

KEY METRICS
  • Do patient advocacy groups that your organizations support fund clinical trial studies?
  • How much impact do you think initiatives such as the proposed 21st Century Cures Act could have on patient advocacy strategies at your company?
  • What are the ethical boundaries that you adhere to while working with patient advocacy groups?

SAMPLE KEY FINDING
  • Mapping the advocacy landscape to succeed: Assess the landscape of advocacy and community- interest groups to understand the broad spectrum of players, special interests and possible collaborators. Align objectives with different advocacy groups based on a particular therapeutic area or region. Be transparent while sharing information that can be deemed useful for advocacy groups. Aim to build long-term relationships.

METHODOLOGY

Best Practices, LLC engaged 48 leaders supporting patient advocacy initiatives at 43 biopharmaceutical companies in the United States through a benchmarking survey.


Industries Profiled:
Biopharmaceutical; Biotech; Communications; Pharmaceutical; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; Blue Earth Diagnostics; Boehringer Ingelheim; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Mallinckrodt; Milestone Pharmaceuticals; Natera; Novartis; Novo Nordisk; OTSUKA; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Spark Therapeutics; Theravance; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.